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Objectives: This study aims to assess the safety and efficacy of a biodegradable polymer-
coated Rapamycin-Eluting Stent (Excel) used in conjunction with six-month dual anti-
platelet therapy in daily practice.
Background: The polymeric material of cardiac stents has been reported to adversely affect
the safety profile of the drug-eluting stents and is also suspected to cause serious long-
term complications. It has been proposed that the biodegradable polymer coatings may
reduce such late-stage adverse effects.
Methods: This is a prospective, multi-center registry of 654 patients from across 9 cardiology
centers in India, who were enrolled and exclusively treated with Excel stents between
February 2008 and May 2010. The recommended antiplatelet regimen included clopidogrel
and aspirin for 6 months period, followed by lifelong aspirin therapy.
Results: The study population included 46.94% diabetics, 24.31% smokers, 48.93% hyper-
tensives and 14.98% hyperlipidemics. The cumulative rates of major adverse cardiac events
were 0.153% at discharge and 1.38% at 12 months. The mean percentage of stenosis was
88.24 ± 9.17% No events occurred between 6 and 12 months.
Conclusions: This multi-center registry study on “real world, all comers” has, thus, showed
that EXCEL™ stent which is PLA-coated biodegradable Rapamycin-Eluting Stent exhibited
high efficacy and safety profile in treatment of patients undergoing PCI as evidenced by69 (mobile).
a.com (T. Mhetre).
ociety of India. All rights reserved.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 6 9 1e6 9 5692significantly lower rates of MACE and no case of stent thrombosis. There was no event even
after DAPT was discontinued after 6 months.
Copyright © 2014, Cardiological Society of India. All rights reserved.1. Background
Interventional cardiology has witnessed major break-
through with introduction of first-generation drug-eluting
stents (DES) because of their efficacy in reducing in-stent
restenosis and target lesion revascularization (TLR) rates
compared with bare-metal stents.1e3 But the initial enthu-
siasm has been tempered by concerns about their long-term
safety, particularly numerically higher rates of late and very
late stent thrombosis, which has been associated with
catastrophic consequences.4e7 This has lead to continuous
search for newer development in order to improve perfor-
mance of drug-eluting stents worldwide including use of
biodegradable polymers, bioresorbable stents etc. The
mechanisms of late or very late stent thrombosis after DES
implantation have not yet been clarified, but the stent
platform design, the toxicity of active drug and the durable
polymer coatings are considered potentially relevant to this
problem. Several histopathological studies have indicated
that the durable polymer coatings of DES, which were
associated with hypersensitivity reactions directed against
the polymer, localized vascular inflammation, apoptosis of
smooth muscle cells, and thrombogenic reactions, may play
significant roles in late or very late stent thrombosis.8e11
Based on this rationale, biodegradable polymer coatings
have been used in some newer generation DESs, including
the Excel stent. The efficacy of various biodegradable poly-
mer-coated drug-eluting stents (DES) has been shown to
have non-inferior clinical and angiographic outcomes in
several randomized trials.12e15
Excel stent (C51H79NO13, molecular weight 914.2), one of
the new generation drug-eluting stent represents a break-
through in biodegradable coating technology. This reduces the
inflammatory effects on vascular endothelial cells caused by
the durable polymer coating residual on the other drug-
eluting stents.
In Excel drug-eluting stent, the polymer is asymmetrically
coated onto the abluminal side of the stent only ensuring that
the optimal amount of drug is released into the wall of the
blood vessel. This effectively inhibits intimal hyperplasia and
significantly reduces the incidence of post-stenting reste-
nosis, thus, achieving complete vascular endotheliasation.
Total rapamycin dosage varies from 195 to 376 mg per stent
according to the stent length. The stent platform is a laser-cut,
316LVM stainless steel, open cell design with strut thickness
of 0.0044 inches.
The objective of this study was to evaluate the long-term
safety and efficacy of the Excel stent along with 6-month
dual antiplatelet therapy (DAPT) for the treatment of coro-
nary artery lesions in “real-world” practice.2. Materials and methods
The e-EXCEL registry is a post marketing surveillance multi-
center, prospective study of patients who underwent suc-
cessful Excel stent implantation at 9 cardiology centers in
India between February 2008 andMay 2010. For the purpose of
this study, patients who had device or procedural failure; who
received >1 stent other than the protocol stent; or had con-
traindications for DAPT; heart function worse than New York
Heart Association functional class III; or a planned upcoming
surgery were excluded. Institutional Ethics Committee
approval was taken and a written informed consent was ob-
tained from each enrolled patient before participation.3. Definitions, follow-up and outcomes
The rate of major adverse cardiac events (MACE) was the pre-
determined primary outcome. MACE is defined as a composite
of cardiac death, non fatal myocardial infarction (MI), and TLR
at the time of discharge as well as 6,9 and 12 months after
stent implantation. In-stent late lumen loss and binary
restenosis at 9 months, and cumulative thrombotic event
rates up to 12 months post index procedure were stated as the
secondary outcomes.
Unless a non-cardiac cause could be clearly established on
clinical or pathological examination, all deaths were consid-
ered to be due to a cardiac cause. Myocardial infarction (MI)
was diagnosed based one development of new pathological Q
waves on the ECG in more than 2 contiguous leads; elevation
of creatinine kinase myocardial band isoenzyme to three
times the upper limits of normal (ULN) after the procedure
during index hospitalization; and/or cardiac enzyme level
more than twice the upper normal limit thereafter. Any repeat
intervention inside the implanted stent or within 5 mm
segment proximal/distal to the stent during the index proce-
dure, is defined as TLR. According to Academic Research
Consortium (ARC) criteria, stent thrombosis is classified as
definite, probable and possible.
Off-label indications of the Excel stent included patients
with acute MI or who had lesions in the left main coronary
artery or ostial, bifurcated or totally occluded lesions, as well
as lesions that did not meet the manufacturer's instructions
for use for the RES.4. Data collection and data management
Demographic, clinical and angiographic data and information
on the follow-up variables was prospectively collected on
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 6 9 1e6 9 5 693case-report forms and submitted to a data coordination cen-
ter. Third party data management team was used to audit the
consistency and accuracy of the data-including baseline, in-
hospital, and follow-up outcomes. At least 15% of patients in
each center were randomly selected for audit checks. In case
of discrepancy between the case-report forms versus source
documentation, all data from that particular center were
audited. Visual estimation of lesion characteristics in relation
to those in the index procedurewas performed by the operator
and the procedures were recorded for follow up and auditing.
If a patient underwent angiographic follow up, coronary an-
giograms obtained at baseline, procedure completion, and
follow-up were also audited and kept in the patient records as
source document for data verification. Binary restenosis was
defined as >50% diameter stenosis at follow up and was
classified as in-stent if inside the stent or in-segment if
located at the stented segment or up to 5 mm proximal or
distal to the stents.5. Statistical analysis
SAS v9.1.3 was used for carrying out all statistical analyses.
Standard descriptive statistics were used for describing the
baseline, lesion, and procedural characteristics and also for
explaining the clinical results for all patients. Continuous
variables were presented as mean ± SD and range, and cate-
gorical variables were presented as numbers and percentages.
Descriptive data of the patient population and serious adverse
events were compiled as per protocol specified time intervals.
The one year clinical outcome data includes stratified ana-
lyses according to the presence or absence of DM, ACS, acute
ST-elevation myocardial infarction, left anterior descending
artery, multi-vessel disease, reference vessel diameter, LVEF,
small-vessel disease, and long-lesions. The MACE-free sur-
vival curve was calculated by the KaplaneMeier method.Table 1 e Baseline clinical characteristics of the inclusive
patients (n ¼ 654).
Observed index n%
Diabetes 307 (46.94%)
Smoking 159 (24.31%)
Hypertension 320 (48.93%)
Hyperlipidemia 98 (14.98%)
Previous H/O MI 229 (35.02%)
Previous H/O Angina 367 (56.12%)6. Results
This study includes a total of 654 patients who underwent PCI
having symptomatic coronary artery disease (CAD), of which
86.39%patients were male and remaining 13.61% patients
were female. The baseline clinical characteristics of the in-
clusive patients are summarized in Table 1. The study popu-
lation included 46.94% diabetics, 24.31% smokers, 48.93%
hypertensives and 14.98% hyperlipidemics. Among these, 35%
had previous history of MI (Myocardial Infarction) and 56.12%
were reported to have previous history of angina. Nearly
three-fourth of the patients (70.34%) had single-vessel disease,
22.78% had double-vessel disease and 6.88% had a triple-
vessel disease (Table 2). The lesion and stent characteristics
of these patients are detailed in Tables 3 and 4.
EXCEL™ stents were implanted in all of these patients and
no device related complications were noticed in the peri-
operative period. A total of 691 EXCEL stents were implan-
ted, with an average of 1.06 ± 0.148 stents per patient (range
1e3) (Table 4). The mean stent diameter was 3.00 ± 0.32 mm
(range 2.5e3.5) and mean stent length was 20.31 ± 06.07 mm
(range 14e36). The device success rate for EXCEL stents was100% with 46.64% stent(s) implantations post-dilation. Of the
remaining, 2.59% received stents with overlapping, 20.64%
were having thrombotic lesion(s) prior to the procedure and
1.83% had lesion(s) at bifurcation.
Four patients were lost to follow up after discharge and 650
were analyzed for MACE at 6, 9 and 12 month period. The
details of themajor cardiac adverse events at discharge and at
the end of 6, 9 and 12 month evaluation periods are shown in
Table 5(a) and (b). At the time of discharge, there was only 01
cardiac death. A cumulative of 7 (1.08%) patients had suffered
from cardiac death between discharge and 6-month follow up,
while 2 (0.308%) were reported to suffer from MI. Of these 2
cases of MI, one was revealed to undergo TVR (target vessel
revascularization). Thus, there were 8 cases of new MACE
between the discharge and 6-month period making a cumu-
lative of 9 (1.38%) cases of MACE at the end of 6-month period.
By the end of 9-month period, all of the 641 patients that un-
derwent evaluation were found to be MACE-free. The mean
percentage of stenosis was 88.24 ± 9.17% (range 65e100).7. Discussion
This post marketing surveillance study characterizes one of
the largest prospective single arm studies in India designed to
support the long-term safety and efficacy of the Excel stent for
treatment of coronary artery lesions in “real-world” clinical
practice. The development of stents has been amajor advance
in the treatment of obstructive coronary artery disease (CAD)
since the introduction of balloon angioplasty.16 Drug-eluting
stents have undergone a series of revolutionary changes
starting from first-generation DESs to polymer-based and now
the focus has been shifted to newer biodegradable polymer
DESs. This newer platform contributes a significant advance-
ment in cardiology, which was intended to lower late ST
associated with persistence of durable polymers after
completion of drug-release. The analysis of 1-year data
collected by the e-Cypher registry suggested a high degree of
safety of RES (Rapamycin-Eluting Stents).17 In several ran-
domized trials, Rapamycin-Eluting Stents have been found to
be highly efficacious and significantly reduce the risk of in-
stent restenosis and target lesion revascularization (TLR)
after percutaneous coronary intervention (PCI).18,19 Single or
multiple centers have conducted clinical registries or obser-
vational studies to find out the safety of RES mainly and, its
efficacy to a lesser extent in a wider variety of indications and
coronary disease presentations as well as to monitor their
broad utilization pattern and performance.
Table 2 e Distribution of patients depending on number
of vessels involved in CAD.
Number of vessels involved in CAD n%
Single vessel disease 460 (70.34%)
Double vessel disease 149 (22.78%)
Triple vessel disease 45 (06.88%)
Table 4 e EXCEL stent characteristics and PCI peri-
operative parameters.
Total stents implanted 691
Mean no. of stent per patient 1.06
Stent diameter (Mean) 3.00 mm
Stent length (Mean) 20.31 mm
Basic peri-operative parameters
Post-dilation 305 (46.64%)
Stent overlapping 17 (2.59%)
Bifurcation 12 (1.83%)
Thrombus lesion 135 (20.64%)
Device success rate 100%
Table 5a e MACE (Major Adverse Cardiac Events)
occurring during post-operative follow up.
Events At discharge
(n ¼ 654)
6 months
(n ¼ 650)
9 months
(n ¼ 650)
12 monthsa
(n ¼ 650)
MACE 1 (0.153%) b9 (1.38%) b9 (1.38%) b9 (1.38%)
Cardiac
death
1 (0.153%) 7 (1.08%) 7 (1.08%) 7 (1.08%)
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 6 9 1e6 9 5694The polymer coatings used in the first-generation DESwere
non-biodegradable. Although RES (Rapamycin-Eluting Stents)
limit restenosis, most of them use a polymer coating as a drug
carrier, long-term adverse vascular pathologies and toxicities
associated with a permanent polymer coating continue to be
of major concern. This had stimulated the development of
non-polymer drug-eluting stent (DES) or DES based on bio-
absorbable polymers. Biodegradable polymer-based stents,
including EXCEL stent, have been shown to be effective in
inhibiting neointimal hyperplasia. The novel PLA material is
gradually biodegraded within approximately 6 months and
eventually becomes water and carbon dioxide after stent im-
plantation. The PLA polymer is now used in the coronary DES
by many manufacturers.19,20
The MEDISTRA trial [Medistra Excel Drug-ElutIng Stent
TRiAl], a first in man study with a bioabsorbable polymer
based Excel DES, showed that despite the inclusion of chal-
lenging “real world cases” the preliminary results were
encouraging with very low MACE rate. Another multi-center
registry trial of EXCEL biodegradable RES [CREATE] docu-
mented satisfactory safety and efficacy profiles, as evidenced
by low rates of major adverse cardiac events and stent
thrombosis up to 5years when used with 6 months of dual
antiplatelet therapy in a “real-world” setting.21 In yet another
single-center experience with complex patients and lesions,
the EXCEL stent implantation with 6-month dual antiplatelet
treatment proved to markedly reduce the incidence of 24-
month ISR and MACE.22
In the study of 100 patients, overall MACE rate at one-year
was better than the results of other studies for the currently
marketed DES.17 The current studywas conducted at 9 centers
as an open-label study involving 654 patients having symp-
tomatic CAD (coronary artery disease) and qualifying for
percutaneous coronary intervention (PCI). The mean per-
centage of stenosis was 88.24 ± 9.17%.Table 3 e Lesion characteristics of inclusive patients
(n ¼ 654): number, target and type of lesions.
a. Number of lesions in patients (n ¼ 654) n%
One lesion 545 (83.33%)
Two lesion 90 (13.76%)
Three lesion 19 (02.91%)
b. Target lesion locations (n ¼ 782) n%
LAD 542 (69.31%)
RCA 130 (16.62%)
LCX 76 (09.72%)
Others 34 (04.3 5%)
c. Type of lesions (AHA/ACC classification) (n ¼ 782) n%
Type-A 434 (55.50%)
Type-B1 285 (36.45%)
Type-B2 and Type-C 63 (08.05%)The overall clinical success rate of the EXCEL™ stent,
indicated by the percentage of MACE-free patients, was found
to be 99.84% at the time of discharge and 98.76% at the end of 6
months and 9 months. The overall clinical success remains to
be 98.76% at 12month follow-up. This is evenmore significant
where almost half of the patient population enrolled were
diabetic, thereby increasing complexity and worsening the
prognosis. There has been no withdrawal of any of the study
patients or any death due to AE or SAEs apart from those
comprising the primary efficacy endpoints in this study.
These results are in line with similar studies conducted with
other biodegradable polymer-based Rapamycin-eluting
stents.18,19,20,218. Study limitations
Any post marketing surveillance registry has study limitation
of being single armwith no control arm for direct comparison.
Since patients treated with other than Excel stent during theMI 0 (0%) b2 (0.308%) b2 (0.308%) b2 (0.308%)
TVR 0 (0%) 1 (0.154%) 1 (0.154%) 1 (0.154%)
n ¼ No. of evaluable patients.
MACE ¼Major Adverse Cardiac Events; MI ¼Myocardial Infarction.
TVR ¼ Target Vessel Revascularization.
a 12 month visit: All 641 patients after the 9 month evaluation
period are alive and have not been reported to have any CAD
symptoms until the time of preparation of this report. Out of these
patients, 380 patients have completed the 12 month follow up
period and the remaining patients are still under follow up for the
12 month. However, all the patients who have completed their 70%
follow up period are considered as treatment completers per pro-
tocol patients' treatment compliance.
b Out of the 2 patients that were reported with MI and had un-
dergone angiography, the reports revealed that one patient had the
complication of TVR and had undergone revisualization. However,
both the events were recorded in the same patient, thus the cu-
mulative MACE at 6-month period onwards remained 9.
Table 5b e Success rate during post-operative follow up.
No. of Patients
who
At
discharge
6
months
9
months
12
months
Underwent follow
up
654 649 643 380a
MACE-free 653 641 641 641
Clinical success rate 99.84% 98% 98% 98%
MACE ¼Major Adverse Cardiac Events; MI ¼Myocardial Infarction.
TVR ¼ Target Vessel Revascularization.
a 12 month visit: All 641 patients after the 9 month evaluation
period are alive and have not been reported to have any CAD
symptoms until the time of preparation of this report. Out of these
patients, 380 patients have completed the 12 month follow up
period and the remaining patients are still under follow up for the
12 month. However, all the patients who have completed their 70%
follow up period are considered as treatment completers per pro-
tocol patients' treatment compliance.
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 6 9 1e6 9 5 695index procedure were excluded, therefore, no information
was collected on other DES. Thismight lead to selection bias to
some extent.9. Conclusion
The current multicenter registry study on “real world, all
comers” has thus shown that EXCEL™ stent exhibits high ef-
ficacy and safety profile in treatment of patients undergoing
PCI. The 1-year incidence of MACE was significantly lower as
compared to previously published data. There was no inci-
dence of stent thrombosis. This study also underlines that
6months DAPT is safe enough for Excel™ DES.Conflicts of interest
All authors have none to declare.r e f e r e n c e s
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